ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0084

Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function

Jeremy Morrissette1, Vinh Dang2, Jemy Varghese2, Zachary Lanzar1, Junior Nguyen2, Emily Landy3, Anastasia Frank-Kamenetskii4 and Scott Canna2, 1University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3University of Pittsburgh, Pittsburgh, PA, 4CHOP/UPENN, Philadelphia, PA

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, cytokines, Interleukins, T Cell, TH17 Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0066–0095) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Interleukin 18 (IL-18) is an inflammasome-activated cytokine that canonically amplifies interferon-gamma (IFNg) production and cytotoxicity by CD8 T-cells (CD8Ts) and Th1 CD4 T-cells (CD4Ts). It is inhibited by the circulating high affinity antagonist, IL-18 binding protein (Il18bp). In certain contexts, IL-18 amplifies non-Th1 responses including Th2, Th17, and Treg. Despite its likely pathogenic role in autoinflammation, clinical observations suggest a possible immunoregulatory role in CD4T-mediated autoimmunity. We sought to understand the role of excess IL-18 in the mixed Th1/17 experimental autoimmune encephalomyelitis (EAE) model of central nervous system autoimmunity.

Methods: EAE was induced via immunization with a complete Freund’s adjuvant/Myelin Oligodendrocyte Glycoprotein peptide (MOG35-55) emulsion and pertussis toxin in the following mice: mice deficient in Il-18bp (Il18bp-/-), with transgenic overproduction of mature IL-18 (Il18tg), transgenic for a T-cell receptor recognizing MOG35-55 (2D2 mice), and relevant controls . EAE was monitored by daily clinical scoring of ascending paralysis. Cell number and cellular protein phenotype were determined by flow cytometry.

Results: We hypothesized that systemic excess IL-18, would amplify autoreactive T-cell activation and lead to more severe EAE, but both Il18bp-/- and Il18tg mice were profoundly protected from EAE (Fig. 1). Protection from EAE in Il18bp-/- mice depended on IFNg. Draining lymph nodes and spleens from Il18bp-/- mice showed a modest increase in IFNg-producing CD4Ts and equivalent IL-17-producing CD4Ts. Spinal cords demonstrated fewer CD4T cells but comparable markers of Th function/polarization on a per-cell basis. There was increased infiltration of CD8Ts relative to CD4Ts in spinal cords of Il18bp-/-mice (Fig. 2A). 2D2 mice have an abundance of MOG autoreactive CD4Ts and very few CD8Ts (due to allelic exclusion). Paradoxically, Il18bp-/-;2D2 mice developed more severe EAE than control 2D2 mice (Fig.1A), suggesting that an increase in precursor autoreactive CD4Ts and/or loss of CD8Ts switches the effect of excess IL-18 from protective to pathogenic. Sensitivity to EAE was restored in Il18bp-/-mice only after transfer of >5 million autoreactive 2D2 CD4Ts. Further, ex vivo culture with IL-18 improved CD8Ts ability to inhibit EAE while CD8-depletion substantially, but incompletely, diminished protection in Il18bp-/- mice (Fig.2B).

Conclusion: These data suggest the IL-18 can amplify both autoreactive CD4T and previously described CD8 T suppressor cells but the latter dominate with a physiologic T cell repertoire. Excess IL-18 may function to preferentially augment CD8T suppressor function to clear autoreactive CD4T and mediate protection in EAE. This may inform novel strategies to amplify endogenous suppressive T cells or enhance cellular therapeutics in the treatment of autoimmune diseases.

Supporting image 1

Fig. 1: Excess IL_18 protects against EAE development with a physiologic T cell repertoire. Il18bp-/-, 2D2, 2D2;Il18bp-/- (A), or Il18tg (B) mice underwent EAE immunization on day 0 with daily clinical EAE scoring compared to WT control mice.

Supporting image 2

Fig. 2: Excess IL_18 enriches CD8 T cells and depends on CD8 T cell function for protection. Spinal cords were analyzed by flow cytometry from WT and Il18bp-/- mice at peak disease (day 19 to 21) and the ratio of CD4 to CD8 T cells is represented (A). Mean clinical EAE score of WT and Il18bp-/- mice receiving isotype control (LIF2 Rat IgG2b) or CD8 depleting antibody (YTS169.4) q3d starting on day 0 (B).


Disclosures: J. Morrissette: None; V. Dang: None; J. Varghese: None; Z. Lanzar: None; J. Nguyen: None; E. Landy: None; A. Frank-Kamenetskii: None; S. Canna: Apollo Therapeutics, 2, Novartis, 12, Site PI for industry-sponsored trial, PracticePoint CME, 6, Simcha Therapeutics, 2, Sobi, 6.

To cite this abstract in AMA style:

Morrissette J, Dang V, Varghese J, Lanzar Z, Nguyen J, Landy E, Frank-Kamenetskii A, Canna S. Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/excess-il-18-protects-from-experimental-autoimmune-encephalomyelitis-mainly-via-preferential-augmentation-of-suppressor-regulatory-over-autoreactive-t-cell-function/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/excess-il-18-protects-from-experimental-autoimmune-encephalomyelitis-mainly-via-preferential-augmentation-of-suppressor-regulatory-over-autoreactive-t-cell-function/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology